216 related articles for article (PubMed ID: 30045750)
1. SWATH-MS based quantitative proteomics analysis reveals that curcumin alters the metabolic enzyme profile of CML cells by affecting the activity of miR-22/IPO7/HIF-1α axis.
Monteleone F; Taverna S; Alessandro R; Fontana S
J Exp Clin Cancer Res; 2018 Jul; 37(1):170. PubMed ID: 30045750
[TBL] [Abstract][Full Text] [Related]
2. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming.
Zhao F; Mancuso A; Bui TV; Tong X; Gruber JJ; Swider CR; Sanchez PV; Lum JJ; Sayed N; Melo JV; Perl AE; Carroll M; Tuttle SW; Thompson CB
Oncogene; 2010 May; 29(20):2962-72. PubMed ID: 20228846
[TBL] [Abstract][Full Text] [Related]
3. HIF-α Promotes Chronic Myelogenous Leukemia Cell Proliferation by Upregulating p21 Expression.
Chen H; Shen Y; Gong F; Jiang Y; Zhang R
Cell Biochem Biophys; 2015 May; 72(1):179-83. PubMed ID: 25596666
[TBL] [Abstract][Full Text] [Related]
4. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.
Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G
Cancer Lett; 2015 May; 360(2):245-56. PubMed ID: 25697481
[TBL] [Abstract][Full Text] [Related]
5. Curcumin modulates chronic myelogenous leukemia exosomes composition and affects angiogenic phenotype via exosomal miR-21.
Taverna S; Fontana S; Monteleone F; Pucci M; Saieva L; De Caro V; Cardinale VG; Giallombardo M; Vicario E; Rolfo C; Leo GD; Alessandro R
Oncotarget; 2016 May; 7(21):30420-39. PubMed ID: 27050372
[TBL] [Abstract][Full Text] [Related]
6. Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia cells growth: a possible role for exosomal disposal of miR-21.
Taverna S; Giallombardo M; Pucci M; Flugy A; Manno M; Raccosta S; Rolfo C; De Leo G; Alessandro R
Oncotarget; 2015 Sep; 6(26):21918-33. PubMed ID: 26116834
[TBL] [Abstract][Full Text] [Related]
7. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Siah2 Ubiquitin Ligase by Vitamin K3 Attenuates Chronic Myeloid Leukemia Chemo-Resistance in Hypoxic Microenvironment.
Huang J; Lu Z; Xiao Y; He B; Pan C; Zhou X; Xu N; Liu X
Med Sci Monit; 2018 Feb; 24():727-735. PubMed ID: 29400343
[TBL] [Abstract][Full Text] [Related]
9. [Effects of RNA interference targeting hypoxia-inducible factor-1alpha (HIF-1alpha) on chemosensitivity of leukemia K562 cells towards homoharringtonine].
Li BZ; Zhuang WZ; Chen P; Fu JX
Ai Zheng; 2008 Jul; 27(7):723-8. PubMed ID: 18606065
[TBL] [Abstract][Full Text] [Related]
10. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
[TBL] [Abstract][Full Text] [Related]
11. MiR-124-3p/B4GALT1 axis plays an important role in SOCS3-regulated growth and chemo-sensitivity of CML.
Liu YX; Wang L; Liu WJ; Zhang HT; Xue JH; Zhang ZW; Gao CJ
J Hematol Oncol; 2016 Aug; 9(1):69. PubMed ID: 27516205
[TBL] [Abstract][Full Text] [Related]
12. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
13. Foxo3a-mediated overexpression of microRNA-622 suppresses tumor metastasis by repressing hypoxia-inducible factor-1α in ERK-responsive lung cancer.
Cheng CW; Chen PM; Hsieh YH; Weng CC; Chang CW; Yao CC; Hu LY; Wu PE; Shen CY
Oncotarget; 2015 Dec; 6(42):44222-38. PubMed ID: 26528854
[TBL] [Abstract][Full Text] [Related]
14. MiR-152-3p promotes the development of chronic myeloid leukemia by inhibiting p27.
Wang L; Wang Y; Lin J
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8789-8796. PubMed ID: 30575920
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
Lin TY; Chen KC; Liu HJ; Liu AJ; Wang KL; Shih CM
PLoS One; 2016; 11(5):e0156260. PubMed ID: 27228340
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and chemical characterization of Cynara cardunculus L. extract and its potential use as co-adjuvant therapy of chronic myeloid leukemia.
Russo A; Perri M; Cione E; Di Gioia ML; Nardi M; Cristina Caroleo M
J Ethnopharmacol; 2017 Apr; 202():184-191. PubMed ID: 28323047
[TBL] [Abstract][Full Text] [Related]
17. [Mechanism of nuclear translocation of hypoxia-inducible factor-1α in influenza A (H1N1) virus infected-alveolar epithelial cells].
Meng X; Guo X; Zhu Y; Xie H; Wang R
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Jan; 32(1):8-13. PubMed ID: 32148224
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.
Jacquel A; Colosetti P; Grosso S; Belhacene N; Puissant A; Marchetti S; Breittmayer JP; Auberger P
Oncogene; 2007 Apr; 26(17):2445-58. PubMed ID: 17043649
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R
Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Ebos JM; Tran J; Master Z; Dumont D; Melo JV; Buchdunger E; Kerbel RS
Mol Cancer Res; 2002 Dec; 1(2):89-95. PubMed ID: 12496355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
